Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended access protocol for patients continuing to benefit from ibrutinib after completion of prior ibrutinib clinical trials
MOH_2018-11-07_004743Phase 4Not yet recruiting
- Sponsor
- Pharmacyclics
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ibrutinib in mantle cell lymphoma (MCL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and Waldenström macroglobulinemia (WM), sponsored by Pharmacyclics. Primary endpoint: Long-term access to ibrutinib. Planned start Jun 2018; status: not yet recruiting.
02
Drugs
ibrutinib
03
Conditions
mantle cell lymphoma (MCL)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on MOH_2018-11-07_004743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-11-07_004743.